孟鲁司特钠联合氯雷他定对咳嗽变异性哮喘患儿血清和诱导痰炎性介质的影响

Effect of montelukast sodium combined with loratadine on inflammatory mediators in serum and induced sputum in children with CVA

目的探讨孟鲁司特钠联合氯雷他定治疗小儿咳嗽变异性哮喘(CVA)的疗效及对血清、诱导痰炎性介质的影响。方法将120例CVA患儿120例随机分为观察组和对照组,每组60例。两组均予以常规综合治疗,对照组加用孟鲁司特钠治疗,观察组在对照组基础上加用氯雷他定治疗。比较两组临床疗效,治疗前后测定血清及诱导痰炎性介质水平。结果观察组总有效率为95.00%,显著高于对照组的81.67%(P<0.05);治疗后,观察组的血清及诱导痰中白细胞介素5(IL-5)、白细胞介素8(IL-8)及嗜酸性粒细胞(EOS)占比显著低于对照组,白细胞介素10(IL-10)显著高于对照组(P<0.05);治疗后观察组血清免疫球蛋白E(IgE)水平显著低于对照组(P<0.05)。结论孟鲁司特钠联合氯雷他定治疗小儿CVA能够有效控制气道及全身炎症,提高临床疗效且安全性好,值得临床推广应用。

Objective To investigate the efficacy of montelukast sodium combined with loratadine in treatment of children with cough variant asthma (CVA),and to observe its influence on inflammatory mediators serum and induced sputum.Methods A total of 120 cases of children with CVA were randomly divided into observation group and control group,with 60 cases each.Both groups received conventional comprehensive treatment.The control group received montelukast sodium treatment,the observation group received loratadine treatment on the basis of control group.The clinical efficacy were compared between the two groups,the levels of inflammatory mediators in serum and induced sputum were measured before and after treatment.Results The total effective rate in the observation group was 95.00%,significantly higher than 81.67% in the control group ( P <0.05).After the treatment,the serum levels and levels in induced sputum of IL-5,IL-8 and EOS in observation group were significantly lower than the control group,and IL-10 was significantly higher ( P < 0.05 );After treatment,the serum level of immunoglobulin E (IgE) in observation group was significantly lower than the control group ( P <0.05).Conclusion Montelukast sodium combined with loratadine can effectively control the airway inflammation and systemic inflammation of children with CVA,can improve clinical efficacy and has good safety,it is worthy of clinical application.